This Article Full Text Full Text (PDF) All Versions of this Article: 43/5/1029    most recent 01.HYP.0000125230.46080.c6v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oikarinen, L. Search for Related Content PubMed PubMed Citation Articles by Oikarinen, L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB LOSARTAN POTASSIUM Related Collections Hypertrophy Electrocardiology Clinical Studies Arrhythmias, clinical electrophysiology, drugs

(Hypertension. 2004;43:1029.)
© 2004 American Heart Association, Inc.

Scientific Contributions

QRS Duration and QT Interval Predict Mortality in Hypertensive Patients With Left Ventricular Hypertrophy

The Losartan Intervention for Endpoint Reduction in Hypertension Study

Lasse Oikarinen; Markku S. Nieminen; Matti Viitasalo; Lauri Toivonen; Sverker Jern; Björn Dahlöf; Richard B. Devereux; Peter M. Okin for the LIFE Study Investigators

From the Division of Cardiology (L.O., M.S.N., M.V., L.T.), Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Sahlgrenska University Hospital/Östra (S.J., B.D.), Göteborg, Sweden; and Division of Cardiology (R.B.D., P.M.O.), Department of Medicine, Weill Medical College of Cornell University, New York, NY.

Correspondence to Dr Lasse Oikarinen, Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland. E-mail lasse.oikarinen{at}kolumbus.fi

Left ventricular hypertrophy is a risk factor for cardiovascular mortality, including sudden cardiac death. Experimentally, left ventricular hypertrophy delays ventricular conduction and prolongs action potential duration. Electrocardiographic QRS duration and QT interval measures reflect these changes, but whether these measures can further stratify risk in patients with electrocardiographic left ventricular hypertrophy is unknown. We measured the QRS duration and QT intervals from the baseline 12-lead electrocardiograms in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, which included hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy randomized to either losartan-based or atenolol-based treatment to lower blood pressure. In the present study, we related study baseline electrocardiographic measures to cardiovascular and all-cause mortality. There were 5429 patients (male 45.8%; mean age 66±7 years) included in the present analyses. After a mean follow-up of 4.9±0.8 years, there were 417 deaths from all causes, including 214 cardiovascular deaths. In separate univariate Cox regression analyses, QRS duration and several QT measures were significant predictors of cardiovascular mortality and all-cause mortality. However, in multivariate Cox analyses including all electrocardiographic measures and adjusting for other risk factors as well as treatment strategy, only QRS duration and maximum rate-adjusted QT_apex interval remained as significant independent predictors of cardiovascular (P=0.022 and P=0.037, respectively) and all-cause mortality (P=0.038 and P=0.002, respectively). In conclusion, in a hypertensive risk population identified by electrocardiographic left ventricular hypertrophy, increased QRS duration and maximum QT_apex interval can further stratify mortality risk even in the setting of effective blood pressure-lowering treatment.

Key Words: electrocardiography • hypertension • mortality • hypertrophy

This article has been cited by other articles:

				S. Baldesberger, U. Bauersfeld, R. Candinas, B. Seifert, M. Zuber, M. Ritter, R. Jenni, E. Oechslin, P. Luthi, C. Scharf, et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists Eur. Heart J., January 1, 2008; 29(1): 71 - 78. [Abstract] [Full Text] [PDF]

				M. S. Lauer, D. Martino, H. Ishwaran, and E. H. Blackstone Quantitative Measures of Electrocardiographic Left Ventricular Mass, Conduction, and Repolarization, and Long-Term Survival After Coronary Artery Bypass Grafting Circulation, August 21, 2007; 116(8): 888 - 893. [Abstract] [Full Text] [PDF]

				G. Schillaci, M. Pirro, T. Ronti, F. Gemelli, G. Pucci, S. Innocente, C. Porcellati, and E. Mannarino Prognostic Impact of Prolonged Ventricular Repolarization in Hypertension. Arch Intern Med, April 24, 2006; 166(8): 909 - 913. [Abstract] [Full Text] [PDF]

				G. Salles, S. Leocadio, K. Bloch, A. R. Nogueira, and E. Muxfeldt Combined QT Interval and Voltage Criteria Improve Left Ventricular Hypertrophy Detection in Resistant Hypertension Hypertension, November 1, 2005; 46(5): 1207 - 1212. [Abstract] [Full Text] [PDF]

				B. Triola, M. B. Olson, S. E. Reis, P. Rautaharju, C. N. B. Merz, S. F. Kelsey, L. J. Shaw, B. L. Sharaf, G. Sopko, and S. Saba Electrocardiographic Predictors of Cardiovascular Outcome in Women: The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study J. Am. Coll. Cardiol., July 5, 2005; 46(1): 51 - 56. [Abstract] [Full Text] [PDF]

				P. M. Okin, R. B. Devereux, S. Jern, S. E. Kjeldsen, S. Julius, M. S. Nieminen, S. Snapinn, K. E. Harris, P. Aurup, J. M. Edelman, et al. Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Treatment and the Prediction of Major Cardiovascular Events JAMA, November 17, 2004; 292(19): 2343 - 2349. [Abstract] [Full Text] [PDF]

				P. M. Okin, R. B. Devereux, M. S. Nieminen, S. Jern, L. Oikarinen, M. Viitasalo, L. Toivonen, S. E. Kjeldsen, S. Julius, S. Snapinn, et al. Electrocardiographic Strain Pattern and Prediction of Cardiovascular Morbidity and Mortality in Hypertensive Patients Hypertension, July 1, 2004; 44(1): 48 - 54. [Abstract] [Full Text] [PDF]